Table 2. Key recent studies exploring... | American Society of Hematology

Table 2.

Key recent studies exploring CAR T-cell therapy in CLL

CAR T-cell therapy	Number of patients with CLL	Prior cBTKi/prior BCL2i	ORR/uMRD in BM, %	Grade ≥3 CRS/grade ≥3 ICANS, %
CD19-4-1BB²⁷	24	19/6	71/58^*	8/25
CD19-4-1BB²⁴	14 (infused)	1/NA	57/21^*	43/7
CD19-4-1BB with ibrutinib²⁹	19	19/11	83/72^†	0/26
CD19-4-1BB²⁶	23	23/15	82/65^*	9/17

CAR T-cell therapy	Number of patients with CLL	Prior cBTKi/prior BCL2i	ORR/uMRD in BM, %	Grade ≥3 CRS/grade ≥3 ICANS, %
CD19-4-1BB²⁷	24	19/6	71/58^*	8/25
CD19-4-1BB²⁴	14 (infused)	1/NA	57/21^*	43/7
CD19-4-1BB with ibrutinib²⁹	19	19/11	83/72^†	0/26
CD19-4-1BB²⁶	23	23/15	82/65^*	9/17

By IGH sequencing.

By flow cytometry.

CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; NA, not available.